Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
825 Eastlake Ave E # G3-200
Seattle, WA 98109Phone+1 206-606-6832Fax+1 206-606-6831- Is this information wrong?
Summary
- Dr. Stephen Smith is a hematologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance and UW Medicine/University of Washington Medical Center. He received his medical degree from University of Southern California School of Medicine and has been in practice 19 years. He is experienced in immunotherapy, lymphoma, stem cell transplantation, and car t-cell therapy.
Clinical Expertise
- Immunotherapy, Lymphoma, Stem cell transplantation, CAR T-cell Therapy
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2005 - 2008
University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 2002 - 2005
Keck School of Medicine of the University of Southern CaliforniaClass of 2002
Certifications & Licensure
OR State Medical License 2011 - Present
CA State Medical License 2003 - Present
WA State Medical License 2013 - 2026
OH State Medical License 2005 - 2012- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Start of enrollment: 2023 Aug 07
Roles: Contact, Principal Investigator
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma Start of enrollment: 2023 Jan 26
Roles: Contact, Principal Investigator
- Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma Start of enrollment: 2021 Aug 03
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsImpact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.Steiner, R., Hwang, S., Khurana, A., Habermann, T., Epperla, N., Annunzio, K., Allen, P., Baird, K., Paulino, D., Alderuccio, J., Lossos, I., David, K., Evens, A., Pan...> ;Blood Advances. 2023 Dec 26
- 3 citationsMosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.Budde, L., Olszewski, A., Assouline, S., Lossos, I., Diefenbach, C., Kamdar, M., Ghosh, N., Modi, D., Sabry, W., Naik, S., Mehta, A., Nakhoda, S., Smith, S., Dorritie,...> ;Nature Medicine. 2024 Jan 1
- 4 citationsHigh-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.Zayac, A., Landsburg, D., Hughes, M., Bock, A., Nowakowski, G., Ayers, E., Girton, M., Hu, M., Beckman, A., Li, S., Medeiros, L., Chang, J., Stepanovic, A., Kurt, H., ...> ;Blood Advances. 2023 Nov 14
- Join now to see all
Journal Articles
- Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaMyo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
Abstracts/Posters
- High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic TrialsStephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin LymphomasStephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell LymphomasStephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management60th American Society of Hematology Annual Meeting - 11/30/2018
Authored Content
- Mantle Cell Lymphoma at ASH 2022 – More Answers, and More QuestionsDecember 2022
Press Mentions
SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018
Professional Memberships
- Member
- Member
- NCCNB-Cell Malignancies, Panel Member
Hospital Affiliations
UW Medicine/University of Washington Medical CenterSeattle, Washington
Fred Hutchinson Cancer CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
